相关实验视频

Updated: Sep 13, 2025

The Arteriovenous AV Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

The Arteriovenous AV Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

Published on: November 2, 2016

在动脉静脉形形中模拟异常血管生成,使用内皮细胞和器官物质进行药理治疗

Eun Jung Oh¹, Hyun Mi Kim², Suin Kwak¹

¹Department of Plastic and Reconstructive Surgery, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.

|July 25, 2025

概括

药理疗法,包括thalidomide,U0126和拉巴胺素,降低了动脉静脉形 (AVM) 内皮细胞的增殖,并降低了miR-135b-5p. AVM血管有机体为研究这些血管异常和测试疗法提供了新的模型.

科学领域:

血管生物学血管生物学
再生医学是一种再生医学.
药理学药理学是指药理学的学科.

背景情况:

动脉静脉形 (AVM) 是一种先天性血管异常,具有异常的动脉-静脉连接.
了解AVM的分子机制对于开发有针对性的药理疗法至关重要.
由于AVM的复杂性,目前的治疗策略经常面临挑战.

研究的目的:

研究特定药理学剂对AVM内皮细胞 (ECs) 和AVM病理学的影响.
建立和验证一种用于使用患者衍生器官的AVM研究的新型体外模型.
确定AVM的潜在治疗点和生物标志物.

主要方法:

分析了人类AVM和健康的血管样本,以及来自AVM的纤维细胞.
隔离的内皮细胞用thalidomide,U0126和拉帕米进行了治疗.
患者的皮肤样本被重新编程成诱导多能干细胞 (iPSC),以创建AVM血管器官.

主要成果:

药物治疗减少了AVM EC的扩散,并降低了生物标志物miR-135b-5p的调节.
血管生成相关基因 (VEGF, ANG2, FSTL1, MARCKS) 的表达减少,而CSPG4的表达增加.
对AVM有机体的治疗降低了EC标记物CD31和α-SMA的表达.

结论:

塔利多米德,U0126和拉巴胺显示出调节AVM细胞过程的潜力.
动脉瘤血管有机体为疾病研究和药物查提供了一个有希望的,生理相关的模型.
通过先进技术进一步改进有机体模型,可以加速个性化AVM治疗.

关键词:

这是一种动脉静脉形形.它们是内皮细胞的内皮细胞.有机生物有机物泰利多胺的使用方法

更多相关视频

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Author Spotlight: Improving Reproducibility in Vascular Organoids Using ROCK Inhibitors and Microwell Confinement

Author Spotlight: Improving Reproducibility in Vascular Organoids Using ROCK Inhibitors and Microwell Confinement

Published on: December 13, 2024

相关概念视频

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...